Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV045
    • TRV250
    • TRV734
  • Products
    • OLINVYK™ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
    • IRS Form 8937
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects

Apr 20, 2022 7:00am EDT

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

Apr 18, 2022 7:00am EDT

OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting

Apr 13, 2022 4:05pm EDT

Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group

Mar 31, 2022 7:02am EDT

Trevena Reports Fourth Quarter and Full Year 2021 Results

Mar 31, 2022 7:00am EDT

Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Mar 30, 2022 7:00am EDT

Trevena to Present at the 2022 BIO CEO & Investor Conference

Feb 03, 2022 7:00am EST

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Jan 27, 2022 9:00am EST

Trevena to Participate in the Upcoming January Conferences

Jan 03, 2022 4:05pm EST

Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Dec 13, 2021 7:00am EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...31
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap